Abstract

Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post–positron emission tomography diagnosis and management change between “AUC-consistent” and “AUC-inconsistent” patients. Results: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post–positron emission tomography diagnosis (28%–21%) and management (32%–17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%). Discussion: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not.
Original languageEnglish
JournalAlzheimers & Dementia
Early online date6 Oct 2019
DOIs
Publication statusPublished - 2019

Cite this

@article{6de562b86a764e338515c05b435d88ef,
title = "Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project",
abstract = "Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post–positron emission tomography diagnosis and management change between “AUC-consistent” and “AUC-inconsistent” patients. Results: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post–positron emission tomography diagnosis (28{\%}–21{\%}) and management (32{\%}–17{\%}) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13{\%}) patients, detected by the AUC with a sensitivity of 93{\%}, and a specificity of 56{\%}. Diagnostic changes occurred independently of AUC status (sensitivity: 57{\%}, specificity: 53{\%}). Discussion: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not.",
author = "{de Wilde}, Arno and Rik Ossenkoppele and Wiesje Pelkmans and Femke Bouwman and Colin Groot and {van Maurik}, Ingrid and Marissa Zwan and Maqsood Yaqub and Frederik Barkhof and Lammertsma, {Adriaan A.} and Biessels, {Geert Jan} and Philip Scheltens and {van Berckel}, {Bart N.} and {van der Flier}, {Wiesje M.}",
note = "Copyright {\circledC} 2019 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2019",
doi = "10.1016/j.jalz.2019.07.003",
language = "English",
journal = "Alzheimers & Dementia",
issn = "1552-5260",
publisher = "Elsevier",

}

TY - JOUR

T1 - Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort

T2 - The ABIDE project

AU - de Wilde, Arno

AU - Ossenkoppele, Rik

AU - Pelkmans, Wiesje

AU - Bouwman, Femke

AU - Groot, Colin

AU - van Maurik, Ingrid

AU - Zwan, Marissa

AU - Yaqub, Maqsood

AU - Barkhof, Frederik

AU - Lammertsma, Adriaan A.

AU - Biessels, Geert Jan

AU - Scheltens, Philip

AU - van Berckel, Bart N.

AU - van der Flier, Wiesje M.

N1 - Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2019

Y1 - 2019

N2 - Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post–positron emission tomography diagnosis and management change between “AUC-consistent” and “AUC-inconsistent” patients. Results: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post–positron emission tomography diagnosis (28%–21%) and management (32%–17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%). Discussion: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not.

AB - Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post–positron emission tomography diagnosis and management change between “AUC-consistent” and “AUC-inconsistent” patients. Results: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post–positron emission tomography diagnosis (28%–21%) and management (32%–17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%). Discussion: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85072845987&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31594684

U2 - 10.1016/j.jalz.2019.07.003

DO - 10.1016/j.jalz.2019.07.003

M3 - Article

JO - Alzheimers & Dementia

JF - Alzheimers & Dementia

SN - 1552-5260

ER -